Last updated: February 23, 2026
What is NDC 23155-0772?
NDC 23155-0772 refers to a specific drug listed in the National Drug Code (NDC) database. The identifier corresponds to Xeljanz (tofacitinib) tablets, manufactured by Pfizer. Tofacitinib is an oral Janus kinase (JAK) inhibitor approved for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Market Overview
Regulatory Status
- Approval Date: Tofacitinib was first approved by the FDA in November 2012.
- Indications:
- Rheumatoid arthritis
- Psoriatic arthritis
- Ulcerative colitis
- Market Authorization: Approved across global markets, including Europe and Japan.
Market Size (2022)
| Parameter |
Data |
| Global sales (2022) |
approximately $1.2 billion |
| US market share (2022) |
65-70% of global sales |
| Number of prescriptions (2022) |
Estimated 1.5 million units |
| Competitive drugs |
Humira, Stelara, Cosentyx |
Key Competitors
- Humira (adalimumab): Estimated $20 billion global annual sales.
- Stelara (ustekinumab): Approximately $8 billion globally.
- Cosentyx (secukinumab): Around $3 billion annually.
Market Trends (2022-2023)
- Growing adoption for ulcerative colitis.
- Increased expansion into new indications.
- Competition intensifies from biosimilars and other small molecules.
Price Analysis
US Pricing (2012-2023)
| Year |
Average Wholesale Price (AWP) per 60mg tablet |
Notes |
| 2012 |
$55 |
Launch period |
| 2015 |
$57 |
Small increase |
| 2018 |
$60 |
Slight rise |
| 2020 |
$62 |
Adjustment for inflation |
| 2023 |
$65 |
Approximate current rate |
Note: Wholesale acquisition costs (WAC) are typically ~10-15% lower than AWP.
Price Compared to Competitors
| Drug |
Typical Price (per month) |
Approval Year |
Indication(s) |
| Xeljanz (NDC 23155-0772) |
~$650 |
2012 |
Rheumatoid, Psoriatic, UC |
| Humira |
~$2,500 |
2003 |
Rheumatoid, Psoriatic, UC, others |
| Stelara |
~$3,200 |
2009 |
Crohn's, Psoriasis, UC |
Xeljanz remains lower priced than biologics such as Humira and Stelara but higher than some biosimilars.
Price Projections (2023-2028)
Factors Influencing Price Trends
- Patent Status: Patents expiring in 2027-2028 could lead to biosimilar competition, pressuring prices.
- Market Expansion: New indications and increased use could sustain prices.
- Regulatory Pathways: Potential biosimilar entrants could introduce lower-cost alternatives.
Projected Price Range
| Year |
Estimated Monthly Price (per 60mg) |
Notes |
| 2024 |
$65-$70 |
Stability expected |
| 2025 |
$65-$75 |
Slight increase or stabilization |
| 2026 |
$70-$80 |
Biosimilar emergence probable |
| 2027 |
$60-$70 |
Biosimilar market entry |
| 2028 |
$55-$65 |
Increased market competition |
Revenue Projections
| Year |
Estimated Global Sales |
Assumptions |
| 2023 |
$1.2 billion |
Base case; steady growth |
| 2024 |
$1.3 billion |
Slight increase with expanded indications |
| 2025 |
$1.4 billion |
Post-approval of new formulations or indications |
| 2026 |
$1.6 billion |
Biosimilar market entry affects competition |
| 2027 |
$1.4 billion |
Patent expiration impacts sales |
Risks to Price and Revenue
- Biosimilar and generic market entry.
- Regulatory delays or additional indications.
- Pricing policies of payers and healthcare providers.
- Market shifts towards oral small molecules versus biologics.
Key Takeaways
- NDC 23155-0772 (Xeljanz) is a mid-to-high priced JAK inhibitor with annual sales exceeding $1 billion.
- Price stability has persisted since launch, with recent minor increases aligned with inflation.
- The competitive landscape features biosimilars and oral drugs, with patent expiry potentially reducing prices after 2026.
- Revenue growth will rely on expanding indications, regulatory approvals, and market penetration.
- Price erosion is probable starting in 2027 with biosimilar competition.
FAQs
Q1: When is the patent expiry for Xeljanz?
Patent protections expire around 2027-2028, opening the market to biosimilars.
Q2: How does Xeljanz’s price compare to biologics?
It is significantly less expensive than biologics like Humira or Stelara but remains high compared to biosimilars.
Q3: What indications are expected to drive future sales?
Ulcerative colitis is a primary growth area; additional indications include juvenile idiopathic arthritis and other autoimmune diseases.
Q4: Will biosimilars significantly impact prices?
Yes, biosimilar entry is expected to reduce prices by 20-40% post-2027.
Q5: How does market competition influence prices?
Intensified competition from biosimilars and alternative oral agents tends to decrease prices, especially after patent expiry.
References
- U.S. Food and Drug Administration. (2012). Xeljanz (tofacitinib citrate) label.
- IQVIA. (2022). Top Selling Biologics and Small Molecules.
- EvaluatePharma. (2022). Oncology and immunology market data.
- FiercePharma. (2023). Biosimilar market dynamics.
- Centers for Medicare & Medicaid Services. (2022). Drug price and utilization data.
[1] U.S. Food and Drug Administration. (2012). Xeljanz (tofacitinib citrate) label.
[2] IQVIA. (2022). Top Selling Biologics and Small Molecules.
[3] EvaluatePharma. (2022). Oncology and immunology market data.
[4] FiercePharma. (2023). Biosimilar market dynamics.
[5] Centers for Medicare & Medicaid Services. (2022). Drug price and utilization data.
